# MS DISEASE MODIFYING THERAPIES

Past, Present, and Future

Barry Hendin, MD Clinical Professor of Neurology University of Arizona School of Medicine Director Banner University Medicine Neuroscience Institute, Comprehensive MS Clinic PGY 49

#### PAST: UNDERSTAND IT, OBSERVE IT

- Relapse Therapies
  - Steroids or ACTH
- Symptomatic Treatment
- Wellness
- Disease Modifying Therapies
  - None available
  - First DMT became available in 1993

- Diagnostic tools
  - No CT
  - No MRI
- Culture
  - Nihilism
  - Neglect
  - Delayed Diagnosis

#### PRESENT: SLOW IT DOWN

#### FDA Approved Agents

- Five Interferons
- Copolymer (2)
- Tysabri (natalizumab)
- Gilenya (fingolimod)
- > Aubagio (teriflunomide)
- Tecfidera (dimethyl fumarate)
- Lemtrada (alemtuzumab)
- Zinbryta (daclizumab)
- Novantrone (mitoxantrone)

Interferon/Copolymer	Orals	Infusion
<ul><li><u>Positives</u></li><li>Safety</li><li>Long History</li></ul>	<ul> <li><u>Positives</u></li> <li>Convenience</li> <li>Efficacy- ARR approximately 50%</li> </ul>	<ul> <li>Positives</li> <li>Increase efficacy</li> </ul>
Negatives • Efficacy- ARR approximately 30%	Negatives • Safety • Tolerability	Negatives • Risks including PML and Autoimmunity (Zinbryta [daclizumab])

## OCREVUS (OCRELIZUMAB): IS IT CHANGING THE CONVERSATION?

#### Positives

- High Efficacy
- Low Risk

## HOW DO WE CHOOSE?

> When to initiate and with what? (Concept of early effective therapy)

- > Escalations vs. highly effective therapies to start
- > When to change therapies? RIO/NEDA
- > When to stop?

> Don't go to sleep at the wheel; Monitor for suboptimal response!



- Comprehensive Center
- > Vitamin D
- > No smoking
- ▹ Exercise
- > Weight Control
- > Alternative Therapies

## FUTURE: REPAIR IT, END IT

- ► Repair:
- Markers
- Induction: Stem Cell
- Genetic Therapies

